# Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

> **NCT06238024** · PHASE2,PHASE3 · COMPLETED · sponsor: **Suzhou Municipal Hospital of Anhui Province** · enrollment: 108 (actual)

## Conditions studied

- Interleukin-6
- Ischemic Stroke
- Endovascular Treatment

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** NaCl 0.9% 100ml

## Key facts

- **NCT ID:** NCT06238024
- **Lead sponsor:** Suzhou Municipal Hospital of Anhui Province
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-02
- **Primary completion:** 2024-06-25
- **Final completion:** 2024-09-22
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238024, "Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06238024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*